Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Treatment of Adults With Primary Malignant Glioma With Irinotecan Plus Temozolomide

NCT00616005 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00616005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00616005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Treatment of Adults With Primary Malignant Glioma With Irinotecan Plus Temozolomide
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
June 30, 2009
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma